Reflections on Market Access for Personalized Medicine: Recommendations for Europe

被引:28
作者
Payne, Katherine [1 ]
Annemans, Lieven [2 ]
机构
[1] Univ Manchester, Manchester M13 9PL, Lancs, England
[2] Univ Ghent, B-9000 Ghent, Belgium
关键词
economic evaluation; personalized medicine; reimbursement; CLINICAL EFFECTIVENESS; COST-EFFECTIVENESS; HEALTH; REIMBURSEMENT; PERSPECTIVES; DIAGNOSTICS;
D O I
10.1016/j.jval.2013.06.010
中图分类号
F [经济];
学科分类号
02 ;
摘要
This article aims to provide an overview of the current literature focusing on the reimbursement of personalized medicine across the European Union. The article starts by describing types of perspectives that are possible (general public, patient, payer, provider, service commissioner, and policymaker). The description of perspectives also explains the importance of understanding the different possible decision criteria and processes from the various perspectives by taking into account budget constraints. The article then focuses on an example of personalized medicine, namely, the use of companion diagnostic-medicine combinations, to describe the role of reimbursement/payer agencies across the European Union to control the introduction and coverage of such companion diagnostic medicine technologies. The article touches on the strategic challenges and the use of economic evidence to introduce personalized medicine from a health policy perspective. The article also draws on empirical studies that have explored patients' and clinicians' views of examples of personalized medicine to illustrate the challenges for developing patient-centered and timely health care services.
引用
收藏
页码:S32 / S38
页数:7
相关论文
共 22 条
[1]  
Annemans L, BUILDING TOOL EVALUA
[2]   Evolving Research and Stakeholder Perspectives on Pharmacogenomics [J].
Beitelshees, Amber L. ;
Veenstra, David L. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 306 (11) :1252-1253
[3]   Best practice in undertaking and reporting health technology assessments -: Working group 4 report [J].
Busse, R ;
Orvain, J ;
Velasco, M ;
Perleth, M ;
Drummond, M ;
Gürtner, F ;
Jorgensen, T ;
Jovell, A ;
Malone, J ;
Rüther, A ;
Wild, C .
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2002, 18 (02) :361-422
[4]   Delivering a Pharmacogenetic Service: Is There a Role for Genetic Counselors? [J].
Callard, Alice ;
Newman, William ;
Payne, Katherine .
JOURNAL OF GENETIC COUNSELING, 2012, 21 (04) :527-535
[5]   The NICE Diagnostics Assessment Programme [J].
Crabb, Nick ;
Marlow, Mirella ;
Bell, Hanan ;
Newland, Adrian .
HEALTH POLICY AND TECHNOLOGY, 2012, 1 (01) :5-7
[6]   Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription [J].
Fargher, E. A. ;
Tricker, K. ;
Newman, W. ;
Elliott, R. ;
Roberts, S. A. ;
Shaffer, J. L. ;
Bruce, I. ;
Payne, K. .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2007, 32 (02) :187-195
[7]   Patients' and healthcare professionals' views on pharmacogenetic testing and its future delivery in the NHS [J].
Fargher, Emily A. ;
Eddy, Charlotte ;
Newman, William ;
Qasim, Faieza ;
Tricker, Karen ;
Elliott, Rachel A. ;
Payne, Katherine .
PHARMACOGENOMICS, 2007, 8 (11) :1511-1519
[8]   Challenges in the Development and Reimbursement of Personalized Medicine-Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group [J].
Faulkner, Eric ;
Annemans, Leven ;
Garrison, Lou ;
Helfand, Mark ;
Holtorf, Anke-Peggy ;
Hornberger, John ;
Hughes, Dyfrig ;
Li, Tracy ;
Malone, Daniel ;
Payne, Katherine ;
Siebert, Uwe ;
Towse, Adrian ;
Veenstra, David ;
Watkins, John .
VALUE IN HEALTH, 2012, 15 (08) :1162-1171
[9]   The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review [J].
Fleeman, N. ;
Martin Saborido, C. ;
Payne, K. ;
Boland, A. ;
Dickson, R. ;
Dundar, Y. ;
Fernandez Santander, A. ;
Howell, S. ;
Newman, W. ;
Oyee, J. ;
Walley, T. .
HEALTH TECHNOLOGY ASSESSMENT, 2011, 15 (33) :XIII-+
[10]   The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation [J].
Fleeman, N. ;
McLeod, C. ;
Bagust, A. ;
Beale, S. ;
Boland, A. ;
Dundar, Y. ;
Jorgensen, A. ;
Payne, K. ;
Pirmohamed, M. ;
Pushpakom, S. ;
Walley, T. ;
de Warren-Penny, P. ;
Dickson, R. .
HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 (03) :1-+